Immunic, Inc. (NASDAQ: IMUX)

Immunic, Inc. is a late stage biotechnology company focused on developing oral small molecule therapies for neurologic and gastrointestinal diseases. The company is headquartered in New York City with its primary research and development operations in Gräfelfing near Munich Germany. It employs approximately 90 personnel as of November 3 2025. Immunic advances three product candidates: vidofludimus calcium IMU 838 for relapsing and progressive multiple sclerosis and ulcerative colitis, IMU 856 for intestinal barrier restoration in celiac disease inflammatory bowel disease graft versus host disease and potential weight management, and IMU 381 as a next generation molecule for gastrointestinal indications. The company's strategy centers on targeting biologically relevant immunological targets with molecules that have distinct mechanisms of action. Vidofludimus calcium inhibits dihydroorotate dehydrogenase and activates the neuroprotective transcription factor Nurr1. IMU 856 modulates SIRT6 to promote epithelial regeneration and barrier function. IMU 381 builds on the company's chemical and pharmacological research platform to address additional gastrointestinal indications. Each program is supported by preclinical and clinical data that aim to demonstrate safety tolerability and therapeutic activity.

Immunic, Inc. currently does not generate revenue from product sales as it has no approved therapies on the market. The company anticipates future revenue will arise from the commercialization of its product candidates upon obtaining regulatory approval and achieving market acceptance. Revenue would be derived from sales of its oral therapies to patients and healthcare providers. As of September 30, 2025 Immunic held cash and cash equivalents of approximately $35,100,000. The company has raised net cash of approximately $496,300,000 from inception through September 30, 2025 via private and public equity offerings. Immunic expects to continue incurring operating losses while it advances its clinical programs and will require additional funding to sustain operations beyond the next twelve months. The company's liquidity position and ability to secure further financing are key factors influencing its near term outlook.

Immunic, Inc. operates in the competitive biotechnology sector focused on oral therapies for autoimmune and inflammatory conditions. The company differentiates itself through its mechanistic approach combining dihydroorotate dehydrogenase inhibition with neuroprotective and antiviral activities in its lead candidate and through its SIRT6 modulating strategy for intestinal barrier repair. It positions itself as a late stage developer with ongoing Phase 3 trials and supportive Phase 2 data aiming to address high unmet need in multiple sclerosis and gastrointestinal diseases. Immunic competes with other biotech and pharmaceutical companies that are developing oral or injectable therapies for similar indications. The company's competitive advantages include its proprietary chemical scaffolds, early clinical evidence of neuroprotective effects, and a pipeline that addresses both neurologic and gastrointestinal disorders with oral administration. Intellectual property protection for vidofludimus calcium extends to 2041 with potential patent term extension, providing a barrier to entry for rivals. These factors collectively support Immunic's goal of establishing a differentiated position in niche therapeutic areas.

Immunic, Inc. intends to serve patients suffering from relapsing and progressive multiple sclerosis ulcerative colitis celiac disease inflammatory bowel disease graft versus host disease and related gastrointestinal disorders. The company's therapies are designed for outpatient use and would be prescribed by neurologists gastroenterologists and other specialty physicians. Patient populations targeted by Immunic's programs represent significant unmet medical need with limited effective treatment options currently available. Successful commercialization would provide access to oral alternatives that could improve adherence and quality of life for chronic disease sufferers. The company also explores potential applications in weight management through IMU 856's effects on glucagon like peptide 1 levels and food intake observed in preclinical studies. Overall Immunic's customer base comprises individuals seeking novel oral treatments for chronic inflammatory and autoimmune conditions and the healthcare providers who manage their care.